替格瑞洛与吗啡相互作用研究进展

doi:10.19803/j.1672-8629.2020.08.19

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (8): 539-542.
DOI: 10.19803/j.1672-8629.2020.08.19

替格瑞洛与吗啡相互作用研究进展

李宇¹, 柴士伟^1,*, 王晓丹¹, 郝丽梅², 刘芳¹, 忻小晶¹

¹天津中医药大学第一附属医院药学部,天津 300380;
²天津中医药大学第一附属医院心血管科,天津 300380

收稿日期:2020-07-31 修回日期:2020-07-31 出版日期:2020-08-15 发布日期:2020-07-31
通讯作者: ^*柴士伟,男,副主任药师,药事管理。E-mail：chaishiwei791109@sina.com
作者简介:李宇,女,本科,主管药师,临床药学。

Literature Review of Research Progress in Drug Interactions between Ticagrelor and Morphine

LI Yu¹, CHAI Shiwei^1,*, WANG Xiaodan¹, HAO limei², LIU Fang¹, XIN Xiaojing¹

¹Department of Pharmacy, First Teaching Hospital of Tianjin University of TCM, Tianjin 300380, China;
²Cardiovascular Department, First Teaching Hospital of Tianjin University of TCM, Tianjin 300380, China

Received:2020-07-31 Revised:2020-07-31 Online:2020-08-15 Published:2020-07-31

摘要/Abstract

摘要： 替格瑞洛与吗啡常联合用于急性冠脉综合征（acutecoronarysyndrome,ACS）的治疗,研究发现替格瑞洛与吗啡存在不良的药物相互作用,但关于这两种药物相互作用的系统研究较少。本文旨在对替格瑞洛与吗啡的药代-药效学相互作用进行综述,并进一步探讨其作用机制及改善措施,以期为临床合理用药提供参考。

关键词: 替格瑞洛, 吗啡, 药物相互作用

Abstract: Ticagrelor and morphine are often used in combination for the treatment of AMI. Studies have found that ticagrelor has a poor drug interaction with morphine, but there are relatively few studies on the interactions betweenof the two drugs. The aim of this review is intendedwas to summarize the pharmacokinetic-pharmacodynamic interactions between ticagrelor and morphine, and further explore theits mechanism and measures of improvement measures to provide guidance for clinical rational drug use.

Key words: ticagrelor, morphine, drug interaction

中图分类号:

R969.3

李宇, 柴士伟, 王晓丹, 郝丽梅, 刘芳, 忻小晶. 替格瑞洛与吗啡相互作用研究进展[J]. 中国药物警戒, 2020, 17(8): 539-542.

LI Yu, CHAI Shiwei, WANG Xiaodan, HAO limei, LIU Fang, XIN Xiaojing. Literature Review of Research Progress in Drug Interactions between Ticagrelor and Morphine[J]. Chinese Journal of Pharmacovigilance, 2020, 17(8): 539-542.

参考文献

[1] Brar SS,Berg JT,Marcucci R,et al.Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative metaanalysis of individual participant data[J]. J Am Coll Cardiol,2011,58(19):1945-1954.
[2] Ibanez B,James SA,Gewall S,et al.2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)[J].Eur Heart,2018,39(2):119-177.
[3] Teng R,Oliver S,Hayes MA,et al.Absorption,distribution,metabolism,and excretion of ticagrelor in healthy subjects[J].Drug Metab Dispos,2010,38(9):1514-1521.
[4] 国家卫生计生委合理用药专家委员会,中国药师协会.冠心病合理用药指南(第2版)[J].中国医学前沿杂志,2018,10(6):1-130.
[5] Parodi G.Editor's Choice-Chest pain relief in patients with acute myocardial infarction.[J].Eur Heart J Acute Cardiovasc Care,2016,5(3):277-281.
[6] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.非ST段抬高急性冠状动脉综合征诊断和治疗指南[J].中华心血管病杂志,2017,45(5):359-376.
[7] 杨玉辉,郑卫星,黄明方,等. 替格瑞洛在中国急性冠脉综合征患者中的早期疗效及安全性观察[J].中国药物警戒,2014,1(7):390-393.
[8] Holzer P.Opioid receptors in the gastrointestinal tract. Regul Pept.[J]. 2009,155(1-3):11-17.
[9] Kubica J,Kubica A,Jilma B,et al.Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors[J]. Int J Cardiol,2016(215):201-208.
[10] Parodi G,Valenti R,Bellandi B,et al.Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients:RAPID(rapid activity of platelet inhibitor drugs) primary PCI study[J].J Am Coll Cardiol,2013,61(15):1601-1606.
[11] Parodi G,Bellandi B,Valenti R,et al.Comparison of double(360mg)ticagrelor loading dose with standard(60mg) prasugrel loading dose in ST-elevation myocardial infarction patients:the rapid activity of platelet inhibitor drugs(RAPID) primary PCI 2 study[J].Am Heart J,2014,167(6):909-1014.
[12] Parodi G,Bellandi B,Xanthopoulou I,et al.Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention[J].Circ Cardiovasc Interv,2015,8(1):1-6.
[13] Franchi F,Rollini F,ChoJR,et al.Impact of morphine on pharmacokinetic and pharmacodynamic profiles of ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J].J Am Coll Cardiol,2015,65(10S):A1751.
[14] Silvain J,Storey GF,Cayla G,et al.P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for STsegment elevation myocardial infarction. The PRIVATE-ATLANTIC study[J].Thromb Haemost,2016,116(2):369-378.
[15] MontalescotG,van’t Hof A W,Lapostolle F,et al. Prehospital ticagrelor in ST-segmentelevation myocardial infarction[J].NEnglJMed,2014,371(11):1016-1027.
[16] Adamski P,Buszko K,Sikora J,et al.Metabolism of ticagrelor in patients with acute coronary syndromes[J]. Sci Rep,2018,8(1):11746.
[17] Teng R,Oliver S,Hayes M,et al.Absorption,distribution,metabolism,and excretion of ticagrelor in healthy subjects[J].Drug Metab Dispos,2010,38(9):1514-1521.
[18] Teng R.Ticagrelor:Pharmacokinetic,Pharmacodynamic and Pharmacogenetic Profle:An Update[J]. Clin Pharmacokinet,2015,54(11):1125-1138.
[19] Hobl EL,Reiter B,Schoergenhofer C,et al.Morphine decreases ticagrelor concentrations but not its antiplatelet effects:a randomized trial in healthy volunteers[J]. Eur J Clin Invest,2016,46(1):7-14.
[20] Teng R,Mitchell P,Butler K.Effect of rifampicin on the pharma-cokinetics and pharmacodynamics of ticagrelor in healthy subjects[J].Eur J Clin Pharmacol,2013,69(4):877-883.
[21] Varenhorst C,Eriksson N,Johansson A,et al.Effect of genetic variations on ticagrelor plasma levels and clinical outcomes[J].Eur Heart J,2015,36(29):1901-1912.
[22] Smith,HS.Opioid metabolism[J]. Mayo Clin Proc,2009,84(7):613-624.
[23] 王伟兰,朱曼,裴斐,等.临床药师对优化治疗方案的作用分析[J].中国药物警戒,2010,7(6):340-342.
[24] Alexopoulos D,Barampoutis N,Gkizas V,et al.Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients:A Randomized Pharmacokinetic/Pharmaco-dynamic Study[J]. Clin Pharmacokinet,2016,55(3):359-367.
[25] Parodi G,Xanthopoulou I,Bellandi B,et al.Ticagrelor crushed tablets administration inSTEMI patients: the MOJITO study[J].J Am Coll Cardiol,2015,65(5):511-512.
[26] Rollini F,Franchi F,Hu J,et al.Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention:the CRUSH Study[J]. J Am Coll Cardiol,2016,67(17):1994-2004.
[27] Rotshteyn Y,Boyd TA,Yuan CS.Methylnaltrexone bromide:research update of pharmacokinetics following parenteral administration[J].Expert Opin Drug MetabToxicol,2011,7(2):227-235.
[28] Holm M,Tornvall P,Henareh L,et al.The movement trial. Originalrese arch[J] J Am Heart Assoc,2019,8(2):e010152.
[29] Kubica J,Kozinski M,Navarese EP,et al.Cangrelor: an emerging therapeutic option for patients with coronary artery disease[J]. Curr Med Res Opin,2014,30(5):813-828.
[30] Siller-matula JM,Specht S,Kubica J,et al.Abciximab as abridging strategy to overcome morphine-prasugrel interaction in STEMI patients[J]. Br J Clin Pharmacol,2016,82(5):1343-1350.

替格瑞洛与吗啡相互作用研究进展

Literature Review of Research Progress in Drug Interactions between Ticagrelor and Morphine

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	张雯雯, 聂西庭, 徐会茹, 冉晔, 田成林, 于生元. 华法林片联合复方氨酚烷胺片致凝血功能极度异常1例分析[J]. 中国药物警戒, 2023, 20(11): 1290-1292.
[2]	谢婧, 关飞. 药物诱发髂腰臀肌自发性出血1例分析[J]. 中国药物警戒, 2023, 20(11): 1299-1302.
[3]	赵瑞, 于晓佳, 安卓玲. 1例大剂量胺碘酮诱发伊伐布雷定闪光现象的药学监护[J]. 中国药物警戒, 2023, 20(10): 1173-1175.
[4]	张泰, 王岩艳. 药用辅料影响诊疗安全研究进展[J]. 中国药物警戒, 2021, 18(5): 492-494.
[5]	吕锦涛, 张丹, 张冰, 萨日娜, 林志健, 张晓朦. 柑橘属中药的药物相互作用研究进展[J]. 中国药物警戒, 2021, 18(5): 495-498.
[6]	杨晓雯, 王晓星. 环孢素联合用药致高钾血症1例及文献分析[J]. 中国药物警戒, 2021, 18(12): 1192-1195.
[7]	程金莲, 欧阳绘天, 靳洪涛, 朱雪琦, 肖爽, 雷翔, 高春升, 刘清泉. 中药临床研究联合用药安全性评价的思考和建议[J]. 中国药物警戒, 2021, 18(1): 4-10.
[8]	袁守军. 几种常用药物联用计算方法的数学瑕疵和一带一线模型法的解决方案[J]. 中国药物警戒, 2021, 18(1): 11-17.
[9]	连玉菲, 刘洪涛, 任炳楠, 赵海静, 王彦泽, 张玥, 田冬冬, 曹格溪, 岳圆圆, 闫莉. 伏立康唑与奥美拉唑联合应用致伏立康唑超快代谢型患者血药浓度增高的分析[J]. 中国药物警戒, 2020, 17(8): 496-501.
[10]	卫红涛, 沈素, 邸宣, 崔璨, 廖音, 宋尧. 长期使用氯喹/羟氯喹不良反应/事件病例分析与药物相互作用[J]. 中国药物警戒, 2020, 17(5): 261-266.
[11]	何桂林, 左丽, 王茜. 替格瑞洛与氯吡格雷药品不良反应/不良事件对比分析[J]. 中国药物警戒, 2019, 16(1): 52-57.
[12]	高千秋, 张浩嘉. 302例他汀类药物相关肌肉系统损害的文献分析[J]. 中国药物警戒, 2018, 15(8): 476-480.
[13]	罗敏, 徐珽. 1例经导管主动脉瓣置入术治疗后患者合用华法林与抗菌药物的药学监护[J]. 中国药物警戒, 2017, 14(9): 555-558.
[14]	吴楠, 张东蕾, 王蕾, 丁年羊, 李婕, 杨扬, 燕丹, 童本定, 魏青. G211T突变与吗啡治疗癌痛有效性及安全性的相关性研究[J]. 中国药物警戒, 2017, 14(1): 14-18.
[15]	李海燕, 胡斌. 质子泵抑制剂与其他药物相互作用的药学监护实践[J]. 中国药物警戒, 2016, 13(7): 429-432.